ArticleFrontiers in pharmacology2025
The value of pharmacist medication therapy management of capecitabine.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Understanding the Cost Consequences of Pharmacist Roles in Managing Long-Term Illnesses: A Systematic Review.Saudi medical journal · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to evaluate the value of the medication therapy management (MTM) provided by an oncologist - pharmacist joint clinic for patients self - administering capecitabine, and to identify intervention programs tailored for pharmacists. Methods: A total of 200 patients were included in the study and were followed up for 1 year. Among them, 100 received MTM and the other 100 were considered a control group. A retrospective, longitudinal comparison of adverse effects (AEs) in capecitabine patients who receive MTM vs. those who do not. During this period, pharmacists systematically reviewed aspects such as drug indications, usage and dosage, as well as the improvement and resolution of AEs, and report the identified problems to the doctor, and discuss with the doctor about prescribing medications for the patient for prevention or treatment. With a particular focus on evaluating the improvement of patients' AEs during the follow - up stage. Results: Our research results indicate that the gastrointestinal tract (χ Conclusion: In the joint outpatient service model of oncologists and pharmacists, pharmacists can manage patients taking oral capecitabine through MTM. This measure can reduce the incidence of drug AEs related to capecitabine, especially those in the gastrointestinal tract, nervous system and blood system, thereby enhancing the safety of patients' medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.